Reasons for non-response in observational pharmacogenetic research

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 8, 2009, Pages 665-671

  Van Wieren de Wijer, Diane B M A ^a,b   Maitland van Der Zee, Anke Hilse ^a   De Boer, Anthonius ^a   Kroon, Abraham A ^c   De Leeuw, Peter W ^c   Schiffers, Paul ^c   Janssen, Rob G J H ^d   Psaty, Bruce M ^e   Van Duijn, Cornelia M ^b   Stricker, Bruno H Ch ^b   Klungel, Olaf H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Case control study; Non response; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

AGE; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEMENTIA; DNA DETERMINATION; DRUG UTILIZATION; FEAR; FEMALE; GENETIC SCREENING; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT INFORMATION; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PHARMACY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RESEARCH SUBJECT; SEX DIFFERENCE; ADULT; ATTITUDE TO HEALTH; CHI SQUARE DISTRIBUTION; FEASIBILITY STUDY; GENETIC PRIVACY; METHODOLOGY; MIDDLE AGED; NETHERLANDS; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REGISTER; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TELEPHONE; WRITING;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CORRESPONDENCE AS TOPIC; FEAR; FEASIBILITY STUDIES; FEMALE; GENETIC PRIVACY; GENETIC SCREENING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; ODDS RATIO; PATIENT SELECTION; PHARMACOGENETICS; QUESTIONNAIRES; REGISTRIES; RESEARCH SUBJECTS; RISK ASSESSMENT; RISK FACTORS; TELEPHONE;

EID: 70349763951     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1764     Document Type: Article

References (14)

1. Kotaniemi JT, Hassi J, Kataja M, et al. Does non-responder bias have a significant effect on the results in a postal questionnaire study? Eur J Epidemiol 2001; 17(9): 809-817.
2. Ronmark E, Lundqvist A, Lundback B, Nystrom L. Non-responders to a postal questionnaire on respiratory symptoms and diseases. Eur J Epidemiol 1999; 15(3): 293-299. (Pubitemid 29262362)
3. Boshuizen HC, Viet AL, Picavet HS, Botterweck A, van Loon AJ. Non-response in a survey of cardiovascular risk factors in the Dutch population: determinants and resulting biases. Public Health 2006; 120(4): 297-308. (Pubitemid 43372700)
4. Tolonen H, Dobson A, Kulathinal S. Effect on trend estimates of the difference between survey respondents and non-respondents: results from 27 populations in the WHO MONICA Project. Eur J Epidemiol 2005; 20(11): 887-898. (Pubitemid 41609488)
5. Korkeila K, Suominen S, Ahvenainen J, et al.Non-response and related factors in a nation-wide health survey. Eur J Epidemiol 2001; 17(11): 991-999.
6. Bakke P, Gulsvik A, Lilleng P, Overa O, Hanoa R, Eide GE. Postal survey on airborne occupational exposure and respiratory disorders in Norway: causes and consequences of non-response. J Epidemiol Community Health 1990; 44(4): 316-320.
7. Kjoller M, Thoning H. Characteristics of non-response in the Danish Health Interview Surveys, 1987-1994. Eur J Public Health 2005; 15(5): 528-535.
8. Gundgaard J, Ekholm O, Hansen EH. The effect of non-response on estimates of health care utilisation: linking health surveys and registers. Eur J Public Health 2008; 18(2): 189-194.
9. Livingston PM, Lee SE, McCarty, Taylor HR. A comparison of participants with non-participants in a population-based epidemiologic study: the Melbourne Visual Impairment Project. Ophthalmic Epidemiol 1997; 4(2): 73-81.
10. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007; 81(2): 185-193. (Pubitemid 46174815)
11. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-137.
12. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6): 568-579.
13. Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004; 57(12): 1223-1231.
14. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. Jama 2002; 287(13): 1680-1689.